Table 2. Open in new tab Demographic and...

Patient

Age at Diagnosis, years

Country of Birth

Smear

Time to CC, days

CXR

Drug-resistance Profile

Duration of MDR Therapy, days

Time on Therapy Before BDQ, days

Indication for BDQ

Duration of BDQ Use, days

Tx Outcome

20–40

India

Neg

Normal

Pre-XDR

553

Extensive resistance

186

Completed

40–60

Nigeria

Pos

Cavitary

AFLDR^a

591

Extensive resistance

187

Completed

3^b

>80

Mexico

Pos

101

Abnormal

AFLDR

705

Extensive resistance

Died

60–80

Mexico

Pos

149

Cavitary

MDR

804

523

Extensive resistance/intolerance to drugs

165

Completed

20–40

Armenia

Pos

149

Cavitary

XDR

869

525

Extensive resistance/intolerance to drugs

195

Completed

20–40

India

Neg

Normal

MDR

924

730

Intolerance to drugs

179

Completed

40–60

China

Not done

616

Cavitary

Pre-XDR

1294

620

Treatment failure/poor clinical response to treatment

166

Completed

20–40

Peru

Pos

140

Cavitary

XDR

n/a

Extensive resistance

365

Moved

20–40

Uzbekistan

Neg

Abnormal

Pre-XDR

443

Extensive resistance

158

Completed

40–60

China

Pos

Abnormal

Pre-XDR

732

Extensive resistance

167

Completed

20–40

Armenia

Pos

110

Cavitary

XDR

827

Poor clinical response to treatment

596

Completed

40–60

Philippines

Pos

222

Abnormal

MDR

681

203

Intolerance to drugs

153

Completed

40–60

Philippines

Neg

Cavitary

AFLDR

662

195

Intolerance to drugs

223

Completed

40–60

Philippines

Pos

Abnormal

AFLDR

559

120

Intolerance to drugs

167

Completed

Table 2.

Open in new tab

Demographic and Clinical Features of the Patients

Patient	Age at Diagnosis, years	Country of Birth	Smear	Time to CC, days	CXR	Drug-resistance Profile	Duration of MDR Therapy, days	Time on Therapy Before BDQ, days	Indication for BDQ	Duration of BDQ Use, days	Tx Outcome
1	20–40	India	Neg	36	Normal	Pre-XDR	553	4	Extensive resistance	186	Completed
2	40–60	Nigeria	Pos	42	Cavitary	AFLDR^a	591	57	Extensive resistance	187	Completed
3^b	>80	Mexico	Pos	101	Abnormal	AFLDR	705	2	Extensive resistance	86	Died
4	60–80	Mexico	Pos	149	Cavitary	MDR	804	523	Extensive resistance/intolerance to drugs	165	Completed
5	20–40	Armenia	Pos	149	Cavitary	XDR	869	525	Extensive resistance/intolerance to drugs	195	Completed
6	20–40	India	Neg	27	Normal	MDR	924	730	Intolerance to drugs	179	Completed
7	40–60	China	Not done	616	Cavitary	Pre-XDR	1294	620	Treatment failure/poor clinical response to treatment	166	Completed
8	20–40	Peru	Pos	140	Cavitary	XDR	n/a	0	Extensive resistance	365	Moved
9	20–40	Uzbekistan	Neg	60	Abnormal	Pre-XDR	443	31	Extensive resistance	158	Completed
10	40–60	China	Pos	50	Abnormal	Pre-XDR	732	56	Extensive resistance	167	Completed
11	20–40	Armenia	Pos	110	Cavitary	XDR	827	68	Poor clinical response to treatment	596	Completed
12	40–60	Philippines	Pos	222	Abnormal	MDR	681	203	Intolerance to drugs	153	Completed
13	40–60	Philippines	Neg	60	Cavitary	AFLDR	662	195	Intolerance to drugs	223	Completed
14	40–60	Philippines	Pos	28	Abnormal	AFLDR	559	120	Intolerance to drugs	167	Completed

Patient	Age at Diagnosis, years	Country of Birth	Smear	Time to CC, days	CXR	Drug-resistance Profile	Duration of MDR Therapy, days	Time on Therapy Before BDQ, days	Indication for BDQ	Duration of BDQ Use, days	Tx Outcome
1	20–40	India	Neg	36	Normal	Pre-XDR	553	4	Extensive resistance	186	Completed
2	40–60	Nigeria	Pos	42	Cavitary	AFLDR^a	591	57	Extensive resistance	187	Completed
3^b	>80	Mexico	Pos	101	Abnormal	AFLDR	705	2	Extensive resistance	86	Died
4	60–80	Mexico	Pos	149	Cavitary	MDR	804	523	Extensive resistance/intolerance to drugs	165	Completed
5	20–40	Armenia	Pos	149	Cavitary	XDR	869	525	Extensive resistance/intolerance to drugs	195	Completed
6	20–40	India	Neg	27	Normal	MDR	924	730	Intolerance to drugs	179	Completed
7	40–60	China	Not done	616	Cavitary	Pre-XDR	1294	620	Treatment failure/poor clinical response to treatment	166	Completed
8	20–40	Peru	Pos	140	Cavitary	XDR	n/a	0	Extensive resistance	365	Moved
9	20–40	Uzbekistan	Neg	60	Abnormal	Pre-XDR	443	31	Extensive resistance	158	Completed
10	40–60	China	Pos	50	Abnormal	Pre-XDR	732	56	Extensive resistance	167	Completed
11	20–40	Armenia	Pos	110	Cavitary	XDR	827	68	Poor clinical response to treatment	596	Completed
12	40–60	Philippines	Pos	222	Abnormal	MDR	681	203	Intolerance to drugs	153	Completed
13	40–60	Philippines	Neg	60	Cavitary	AFLDR	662	195	Intolerance to drugs	223	Completed
14	40–60	Philippines	Pos	28	Abnormal	AFLDR	559	120	Intolerance to drugs	167	Completed

N = 14.

Abbreviations: AFLDR, all first-line drug resistant; BDQ, bedaquiline; CC, culture conversion; CXR, chest X-ray; EMB, ethambutol; INH, isoniazid; MDR, multidrug-resistant; n/a, not applicable; Neg, negative; Pos, positive; PZA, pyrazinamide; RIF, rifampin; XDR, extensively drug-resistant; Tx, treatment.

^aResistance to INH, RIF, EMB, PZA.

^bPatient 3 died secondary to cerebral degeneration but completed nearly 2 years of treatment.

This Feature Is Available To Subscribers Only